Body Pharm NAD+ 1000

Body Pharm's NAD+ 1000 mg injectable pen is a research-grade, pre-filled multi-dose pen with a 3 ml cartridge that contains 1000 mg of nicotinamide adenine dinucleotide in total. The dose dial sets the dose directly in milligrams and comes marked at 20, 30, 40 and 50 mg, up to a maximum of 200 mg per day. It is manufactured in accordance with the requirements of Annex 1 of the EU GMP for sterile filling and is supplied in Spain exclusively for laboratory research purposes.

The dose is read off the dial and delivered by the mechanism of the device, rather than being prepared at the laboratory bench. You set the figure on the dial and the pen delivers that dose. That turns the dose into a mechanical, repeatable variable from one administration to the next, which is exactly what a repeat-dose design needs to keep under control. Research buyers in Spain who are comparing NAD+ formats in 2026 are increasingly specifying pre-filled pens for that very reason.

NAD+ 1000 pen: the essentials

• The dose dial sets the dose directly in milligrams, with marks at 20, 30, 40 and 50 mg and up to 200 mg per day, at a dosing accuracy of ±3%. Doses below or between the printed marks can also be set, 10 mg included
• The sealed 3 ml cartridge is multi-dose: you dose from a single reservoir over the whole course of the protocol, without ever reopening the primary container
• 1000 mg per pen gives you 50 doses of 20 mg, 33 of 30 mg, 25 of 40 mg or 20 of 50 mg; the price is €129 per unit plus the flat shipping charge for tracked delivery within Spain
• There are two reference research regimens, and they are alternatives to one another: 10–50 mg two or three times per week for the first 4 weeks and then 20–80 mg two or three times per week, or else 10–20 mg per day on 5 days of the week and then 20–30 mg per day
• Every order comes with the certificate of analysis that is specific to the batch, the fill standard in line with Annex 1 of the EU GMP and device quality to ISO 13485:2016

What is the Body Pharm NAD+ 1000 pen?

The Body Pharm NAD+ 1000 pen is a pre-filled multi-dose subcutaneous injectable pen holding 1000 mg of nicotinamide adenine dinucleotide (CAS 53-84-9) in total. The dose dial sets the dose directly in milligrams, with marks at 20, 30, 40 and 50 mg and up to 200 mg per day, and the pen is intended exclusively for laboratory research purposes.

NAD+ is a coenzyme that is present in every living cell. It is central to redox reactions, to the mitochondrial production of ATP and to sirtuin-mediated signalling. The pen contains a sterile solution of NAD+ in a sealed 3 ml cartridge, which is filled under aseptic conditions in line with Annex 1 of the EU GMP [5]. You set the dose on the dial and administer it by the subcutaneous route.

The format at a glance

• Active ingredient: nicotinamide adenine dinucleotide (NAD+), 1000 mg in total per pen
• Route of administration: subcutaneous, multi-dose pen with a 3 ml cartridge
• Dosing: the dose dial sets the dose in mg, with marks at 20, 30, 40 and 50 mg and up to 200 mg per day
• Classification: for research use only, not an authorised medicine

Protocol guidance on how to structure a titration across these steps can be found in our complete NAD+ dosing protocol; the neighbouring compounds are compared in the longevity peptide catalogue.

Full product specifications

The Body Pharm NAD+ 1000 pen contains 1000 mg of β-nicotinamide adenine dinucleotide (CAS 53-84-9) in total, in a sealed, pre-filled subcutaneous device whose dose dial comes marked at 20, 30, 40 and 50 mg, up to 200 mg per day. It is kept refrigerated at 2–8 °C and is filled under aseptic conditions in line with Annex 1 of the EU GMP [5]. The table below sets out the specifications as they stand in the first quarter of 2026.

The arithmetic is deterministic: every dose deducts its figure in milligrams from the 1000 mg in the cartridge, and whatever remains that does not add up to one more full dose is not delivered. Anyone who is planning titration schedules should turn to the complete NAD+ dosing protocol or compare the economics of the cartridge against other compounds in the longevity peptide catalogue.

Dial dosing: why it matters in research

The dose on this pen is set on the dial, in milligrams, and it is the mechanism of the device that delivers it. That is the point that matters for a protocol: the quantity delivered is a property of the device and not of the operator's technique.

Dosing precision

You set the figure on the dial and the pen delivers that dose. The setting is mechanical rather than estimated, and every batch is put through a dose check against a fill accuracy of ±3%. Anyone who attaches importance to the reproducibility of the dose across several administrations has one variable fewer to record here: the same mark on the dial delivers the same mass in week one and in week six.

Storage and window of use

Store the pen at between 2 and 8 °C and keep it protected from light. While unopened, it keeps for 24 months. Once it has been punctured for the first time, use it within 12 months. If you do not have a refrigerator available, the pen will tolerate up to 30 days at room temperature, with a maximum of 30 °C. Let it come to room temperature before injecting and never freeze it. The 3 ml cartridge remains sealed inside the device for the whole of the series, so a protocol with daily or alternate-day administration is covered without the primary container ever being reopened.

Which designs it suits

For titration schedules with fixed steps, and for repeat-dose studies in which the reproducibility of the dose is the controlled variable, the pen is the cleanest instrument, because the dose that is delivered is fixed by the dial. The dial comes marked at 20, 30, 40 and 50 mg and goes up to 200 mg per day, and doses below or between the printed marks can also be set, 10 mg included. Anyone who is going to carry out a structured titration should check their schedule against the complete NAD+ dosing protocol before placing an order.

NAD+ in research: what the evidence shows (2022–2025)

Research on NAD+ concentrates on its decline with age, on the enzymes that consume it (sirtuins, PARPs, CD38) [1] and on the trials of oral precursors, which have raised blood NAD+ [2] and improved muscle insulin sensitivity [3] in controlled studies. Direct subcutaneous administration, which is what this pen is for, has a great deal less literature behind it and comes from clinic protocols. The summary, with the studies linked to PubMed, is in what is NAD+.

Quality, sourcing and batch traceability

We fill, seal and dose-validate every NAD+ 1000 pen to the EU laboratory standard, in line with Volume 4 of EudraLex and with the requirements of Annex 1 for the manufacture of sterile injectable preparations [5], revised in 2022 and in force since 25 August 2023. Aseptic processing, the integrity of the container closure system and cleanroom classification follow the same framework that applies to authorised sterile products in the EU, even though this pen is supplied as a research reagent and not as an authorised medicine.

Full traceability means three things in practice. Every pen carries a unique batch number that is printed on the pen and on the outer box. A certificate of analysis (CoA) confirms the identity and purity of that specific batch. Retention samples are kept and checked against the batch record. The device quality of the pen body and the cartridge is governed by the conventions of ISO 13485:2016 [6] for quality management systems for medical devices.

Methodology, Body Pharm, first quarter of 2026 We fill, seal and dose-validate every NAD+ 1000 pen to the EU laboratory standard. Every batch is put through a dose check on a minimum of 30 doses per dial mark (20/30/40/50 mg) for a fill accuracy within ±3%, is delivered with a certificate of analysis confirming purity and origin, and two retention samples per batch are kept for 24 months. Research teams can request the batch documentation when they place their order.

Procurement teams who are comparing specifications within our longevity peptide catalogue can request the relevant CoA before placing an order and check it against the step schedule in the complete NAD+ dosing protocol.

Ordering, shipping and returns in Spain

Orders within Spain are shipped with tracking for a flat shipping charge. Most addresses receive the NAD+ 1000 pen within a period of 3–5 working days from dispatch.

Every parcel is sent out in neutral, unbranded outer packaging, with no identification of the product or the category on the outside. The tracking number is sent to you by email at the moment of dispatch; delivery generally takes 3–5 working days.

Returns and confirmation of research purpose

Items that are unused and unopened can be returned within 14 days of receipt for a refund. Once a pen has been activated or the seal on the cartridge has been broken, it can no longer be returned, in keeping with standard practice for the handling of sterile products. At checkout, buyers confirm that the purchase is being made exclusively for laboratory research and not for administration to people.

For the protocol details ahead of ordering, the complete NAD+ dosing protocol works through the two regimens and the dial marks that are cited on this page.

How NAD+ is dosed in a research protocol

The dial on the NAD+ 1000 pen comes marked at 20, 30, 40 and 50 mg and goes up to 200 mg per day; doses below or between the marks can also be set, 10 mg included. The two reference regimens are the intermittent one (10–50 mg two or three times per week for the first 4 weeks, then 20–80 mg two or three times per week) and the daily one (10–20 mg per day, on 5 days of the week, then 20–30 mg per day). You choose one and keep to it, injecting slowly to limit flushing. The detail is in how to dose NAD+.

NAD+ and longevity research: related peptides

NAD+ forms part of a wider catalogue of longevity peptides that are often combined on the basis of mechanistic overlap rather than redundancy. The compounds that are most often studied alongside NAD+ are GHK-Cu, MOTS-c and tesamorelin, each of which addresses its own axis of the biology of cellular ageing.

GHK-Cu is studied for copper-dependent cellular repair and for signalling in the extracellular matrix, adjacent to the NAD+-driven activity of the sirtuins without overlapping with it. MOTS-c is a peptide encoded in the mitochondria with direct mechanistic relevance. The original work by Lee et al. (2015) places MOTS-c within AMPK signalling, upstream of the SIRT1–PGC-1α axis [4]. We have not identified any published study that has formally evaluated the combination of MOTS-c with greater availability of NAD+ in vitro. The protocol guidance is in our MOTS-c dosing guide.

Tesamorelin acts on the GH (growth hormone)/IGF-1 (insulin-like growth factor 1) axis and is normally investigated in parallel rather than as a direct interaction with NAD+. The protocol context is in the tesamorelin dosing guide. As of 2025, no direct data on the co-administration of NAD+ and MOTS-c in humans have yet been published.

Frequently Asked Questions

Is NAD+ 1000 available in Spain for research purposes?

Body Pharm supplies the NAD+ 1000 pen exclusively for the purposes of laboratory research and analysis, and not for human consumption. The pen is a research reagent and not an authorised medicine; it is not intended for self-administration.

What are the shelf life and storage requirements?

Store the pen at between 2 and 8 °C and keep it protected from light. While unopened, it keeps for 24 months. Once it has been punctured for the first time, use it within 12 months. If you do not have a refrigerator available, the pen will tolerate up to 30 days at room temperature, with a maximum of 30 °C. Let it come to room temperature before injecting and never freeze it. The expiry date of the batch is given on the certificate of analysis that is issued with each unit.

Can the pen be used more than once?

Yes. The NAD+ 1000 pen is a multi-dose device: you set the dose on the dial at each administration, until the 1000 mg total in the cartridge has been used up. Between uses it is closed and kept refrigerated. Titration across several doses is the intended use case. The protocol details are in our complete NAD+ dosing protocol.

Is a certificate of analysis available?

A CoA that is specific to the batch is available on request for every NAD+ 1000 pen that is shipped. It covers identity, purity and a check of the fill volume, in line with the fill-and-seal requirements of Annex 1 of the EU GMP [5]. Quote the batch number that is printed on the pen in your request.

What is the difference between NAD+ and NMN/NR?

NAD+ is the active coenzyme. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are oral precursors which the body converts into NAD+. A randomised trial from 2023 using oral NMN at doses of 300, 600 and 900 mg in healthy middle-aged adults showed measurable increases in blood NAD+, largest at 600 and 900 mg [2]. No direct human pharmacokinetic study from 2023–2025 compares subcutaneous NAD+ with oral NMN or NR. The pen forms part of the wider longevity peptide catalogue.

Order the NAD+ 1000 pen

Order Body Pharm's NAD+ 1000 mg injectable pen for €129, with tracked shipping within Spain for a flat shipping charge and a CoA specific to the batch available on request. Add the NAD+ 1000 pen to your cart or request the batch documentation before you buy through our contact page.

Sources

1. Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021. pubmed.ncbi.nlm.nih.gov/33353981
2. Yi L, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience. 2023;45(1):29-43. pubmed.ncbi.nlm.nih.gov/36482258
3. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. pubmed.ncbi.nlm.nih.gov/33888596
4. Lee C, et al. The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metab. 2015. pubmed.ncbi.nlm.nih.gov/25738459
5. European Commission. EudraLex, Volume 4: Good manufacturing practice (GMP) guidelines for medicinal products for human and veterinary use, Annex 1 (manufacture of sterile medicinal products). https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en (accessed October 2026).
6. ISO. ISO 13485:2016, Medical devices — Quality management systems — Requirements for regulatory purposes. https://www.iso.org/standard/59752.html (accessed October 2026).